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Abstract
Melanoma malignum belongs to the group of neoplasms with
the highest lethality. Due to the continuous increase of incidence
in numerous countries, this malignance has become a serious
health problem.
This highly aggressive neoplasm is a source of metastases to
most organs and eo ipso of bad prognosis. Early detection of
the primary tumour and of metastases creates a chance for op-
timal therapy.
The methods of nuclear medicine are becoming more popular
in diagnostics of melanomas because they offer advantages over
traditional methods of anatomic imaging. Functional imaging,
based on the use of modern radiopharmaceuticals frequently
offers more successful identification and characterization of
malignant neoplasms.
Over the last few decades there have been numerous attempts
to utilize, in the diagnostics of melanomas, a number of com-
pounds labelled with radioactive nuclides.
An accepted role in diagnosis of melanoma found a technique
of lymphoscintigraphic mapping of lymphatic nodes and of de-
tection of the sentinel node. In addition, modern positron emis-
sion tomography (PET) with use of 18F-fluorodeoxyglucose has
found acceptance in melanoma diagnostics.
The present review refers to information on the presently used
and potential new radiopharmaceuticals promising effective
melanoma diagnostics.
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Introduction
Melanoma malignum is an aggressive neoplasm, originating
most often in the skin. Less frequent primary foci of melanotic char-
acter are mucosa and ocular retina. The process of neoplastic trans-
formation, leading to the development of melanomas, results from
genetic predisposition and depends on numerous external fac-
tors. Among the indicated principal causes of malignant melano-
ma is enhanced exposure to solar light and probably artificial sour-
ces of ultraviolet light [1–3]. The melanoma is at present a neo-
plasm with the highest yearly increase in incidence among all ma-
lignancies. This increase varies among different populations; how-
ever, among Caucasian populations the increase is estimated
at 3–7% per year [4].
The aggressiveness of such melanomas is characterized by
their ability to form metastases to almost every organ. The most
frequent location of earliest metastases is near lymphatic nodes
and skin. The next most frequent locations of metasta-ses in inter-
nal organs are: brain, lungs, liver, intestines, and kidneys.
Surgical removal of the primary focus in the early phase of the
disease often leads to complete cure. However, occurrence of me-
tastases leads to worsening of the prognosis. Mean 5-year survi-
val for patients with metastases in regional lymphatic nodes varies
between 20 and 50 per cent [5, 6].
An assessment of how advanced the neoplastic process is
plays a dominant role in prognosis and therapy planning. For this
purpose there are several classifications used which take account
of various morphologic characteristics of the primary focus in the
skin, a.o. the depth of skin penetration (Clarks’s scale), the thick-
ness of neoplastic infiltration (Breslow scale), and the presence or
absence and localization of metastases. The length of survival is
determined mostly by localization of metastases and by general
advancement of the neoplastic process [7–9].
Among the noninvasive imaging techniques used for the stag-
ing of the disease and for the detection of metastases, the role of
those belonging to nuclear medicine is increasing steadily. They
are free of the numerous inadequacies of traditional morpholo-
gical imaging techniques such as MRI, CT, and ultrasound. In
anatomic imaging there are instances when differentiation of be-
nign and malignant character are almost impossible; the same
applies to changes post therapy and relapse of neoplasm. Small
metastatic foci, not affecting the morphology of an organ, may
be missed [10].
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For many years investigators had been trying to find new ra-
diopharmaceuticals with a high affinity to melanoma cells. The
accepted role in diagnostics has been granted to lymphoscinti-
graphic mapping of lymph nodes and detection of the sentinel
node. The same position has been granted to PET techniques
utilizing 18F-fluorodeoxyglucose as the marker of malignant cells.
Many other techniques and tracer compounds tested did not have
a sufficiently high uptake by the melanotic cells and/or too slow
elimination from the surrounding tissues. The latter feature result-
ed in a low tumour/non-tumour ratio, which in turn made the pro-
cedure useless for the detection of melanoma foci. Further in the
text the radiopharmaceuticals presently in use for melanoma
diagnostics will be presented. In addition, the methods and ra-
diopharmaceuticals that are only of historic importance and the
new substances which may be potentially useful for melanoma
diagnostics will be reviewed.
Nuclear medicine techniques used at
present for the diagnostics of melanomas
Lymphoscintigraphy — detection of the sentinel
lymph node
In the diagnostics of melanomas, a common acceptance has
been obtained by lymphoscintigraphic detection of the sentinel
lymph node.
For this purpose a number of colloidal substances labelled with
radionuclides have gained common acceptance. At present the
method is a commonly accepted standard in the diagnostics (stag-
ing) of melanomas [11–13].
The lymphatic route is the principal way of spread of melano-
mas from their original focus. The neoplastic cells progressing
via the lymphatic vessels are stopped in the first node on the way;
this node is called a sentinel lymph node. The absence of me-
tastases in the latter, when screened by a histopathologist, indi-
cates that the spread of the melanotic cells through a lymphatic
route has not yet taken place. Such an observation also suggests
with high probability that distant organs are free of metastases.
According to commonly accepted standards, a negative result of
sentinel node ana-lysis for the presence of melanotic cells is
an accepted basis for resignation from elective lymphadenecto-
my dissection. However, the presence of metastases in regional
lymph nodes is found in approximately 20% of patients with pri-
mary focus of melanoma only. In the remaining 80 per cent of
patients, elective lymph node dissection would lead to substan-
tial disorder and post-surgical complications while providing no
therapeutic gain [12, 13].
At the beginning of lymph node mapping, the sentinel node
can be detected by intracutaneous injection of a dye close to the
tumour (isosulfan blue, patent blue). This method detects the sen-
tinel node in 80% of cases [12]. Lymphoscintigraphy with a radio-
active colloid, combined with pre- and intrasurgery scintigraphy
by means of a manual gamma-ray detector increases the detec-
tion rate of the sentinel node to 95 per cent. The colloidal com-
pounds used at present (albumin, sulphur-, tin-, antimonium trisul-
phide colloid, and albumin nanocolloid) are labelled with 99mTc
[12, 13]. After injection of a radiocolloid, the regional lymph nodes
may be imaged using a stationary gamma camera and localized
intra surgically by using a manual gamma-ray detector.
The most difficult localization of the sentinel node by the above
method is encountered in patients with the primary melanoma fo-
cus in the region of the head or neck. This small region contains
numerous clusters of lymph nodes located at small distances. The
injected colloid tracer moves rapidly from the site of injection and
labels numerous lymph nodes. Detection of sentinel nodes in this
area is also made difficult by the close proximity of the original
primary focus of melanoma.
Good results were obtained by Mar and her colleagues by
using the above method in the region of the head and neck and
applying a hybrid SPECT-CT camera for detection while injecting
a sulphur colloid labelled with 99mTc [14].
18F-FDG PET
18F-FDG, i.e. 18F-fluoro-2-deoxy-D-glucose is widely used at
present for oncological, cardiological, and neurological purposes.
This analogue of glucose is preferentially taken up by cells with
high metabolic activity, of which the neoplastic cells form the most
frequent subject of interest. The majority of melanomas belong to
this category. Initial clinical tests made in the 1990s with 18F–FDG
and PET provided results that promised success when using this
method for detection of melanomas and their metastases [15].
The 18F-FDG-PET imaging has certain limitations. The radiop-
harmaceutical is not specific for melanomas. Apart from the foci of
various neoplasms it is taken up by muscles, inflammatory foci,
and the central nervous system [16]. Access — at least in several
countries — to PET is more limited than it is to SPECT imaging.
Pfannenberg and co-workers compared results of imaging
using 18F-FDG PET/CT and using whole body magnetic resonance
imaging (MRI). While comparing results of melanoma foci detec-
tion, in which 64 patients were studied, the accuracy of PET/CT
was 86.7%, of the MRI 78.8%, and the 18F-FDG PET alone yielded
74.3% accuracy. The PET/CT imaging when compared with MRI
was more sensitive where metastases to skin, subcutaneous tis-
sue, and lungs were concerned. The MRI, on the other hand, de-
monstrated better accuracy when tumours of the brain, liver, and
bone marrow were considered. Staging of the disease was most
accurate in patients with advanced melanomas when a combi-
nation of 18F-FDG PET/CT and MRI imaging of several organs like
the brain and liver was applied [17]. Some studies of patients
with melanomas in the early stages demonstrated a low effec-
tiveness of 18F-FDG PET in the assessment of melanoma
spread. Wagner and co-workers assessed the sensitivity of me-
tastases detection to the regional lymph nodes using 18F-FDG
PET as the tool. The sensitivity was low (21%) indicating that this
mode of imaging is not a good alternative to commonly used
techniques of detection of sentinel nodes and their histopatho-
logical evaluation [18].
Radiopharmaceuticals on the market,
which were tested for effectiveness
in melanoma diagnostics
Gallium-67 citrate
First attempts to use 67Ga-citrate for the imaging of melano-
mas indicated high specificity but low sensitivity — in the order of
50 per cent. In the eighties, the use of larger activities of 67Ga com-
bined with modern scintigraphic imaging, mostly SPECT, yielded
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a higher sensitivity of detection [19–21]. Kirkwood and his team,
using an activity of 67Ga citrate of 370 MBq, obtained mean sensi-
tivity of detection of 90% and specificity of 99% when studying me-
tastases to lymph nodes and soft tissues in a group of 67 patients.
A higher percentage of false negative cases were found when me-
tastases were looked for in internal organs (sensitivity of detection
in the thorax reached only 68%). Where the brain was concerned,
the same method did not visualize any of the four metastasis which
were detected using other methods [20].
Present studies indicate better diagnostic efficacy of newer
imaging methods when compared with 67Ga citrate scintigraphy.
Thus, Murata and his co-workers in their studies (1991–2001) of
44 patients with diagnosed melanomas were able to find the ini-
tial focus only in 25 per cent of cases [22]. The Kalif team com-
pared the effectiveness of gallium-67 scintigraphy with PET to-
mography using 18F-FDG (121 patients). This study demonstrat-
ed a higher effectiveness when compared with 67Ga citrate SPECT
scintigraphy. The former method also detected important mela-
noma foci which changed staging in the initial stadium of the di-
sease and required correction of the therapy. Apart from diag-
nostic efficacy, there were other reasons for avoidance of this ra-
diopharmaceutical: the long duration of the procedure (i.e. pla-
nar scintigraphy and SPECT after several days since administra-
tion of 67Ga citrate) and the necessity to use high activities of the
radiopharmaceutical [19].
99mTc-Sestamibi
Methoxyisobutyl isonitrile labelled with 99mTc (99mTc-MIBI), ori-
ginally synthesized for heart perfusion studies, has also been test-
ed for its affinity to several carcinomas. The sensitivity of mam-
mary, pulmonary, and brain neoplasm detection varies between
60 and 85 per cent [23–29]. There have also been attempts to
use the compound for the imaging of melanomas [30–34]. Soler
and co-workers studied the diagnostic efficacy of 99mTc-MIBI in
a group of 30 patients after resection of dermal melanomas. The
sensitivity of detection of metastases of the regional lymph nodes
reached a surprisingly high value — 94%. There was only one
false negative result (1 out of 16 investigated and histologically
verified cases) [33]. Alonso and co-workers studied a group of
81 patients with resected primary focus of melanoma, and they
also obtained a very high sensitivity of metastases detection with
99mTc-MIBI — 92%. Planar scintigraphy revealed 68 from 74 me-
lanoma foci. Most of them were localized in skin (n = 16) and
regional (n = 23) or distant lymph nodes (n = 10). The metastas-
es to internal organs were less numerous (brain: n = 6, lungs:
n = 8, bones: n = 4, breast: n = 1) [34].   According to this au-
thor's opinion, the relative high fraction of false negative results
was due, at least partially, to the poor resolution of the SPECT
camera. This was also the reason for resignation of the use of
scintigraphy for the assessment of the sentinel node by means of
99mTc-MIBI. Histopathology of the resected node was diagnosti-
cally more accurate [30, 32].
123I-iodoamphetamine (123I-IMP)
N-isopropyl-p-123I-iodoamphetamine is a lipophilic derivative
used for brain scintigraphic investigation. Holman et al. discovered
the uptake of 123I-IMP by melanocytes actively synthesizing mela-
nin [10]. Murata with his team, while analyzing 44 patients with
diagnosed melanomas, over 10 years, succeeded to image the
primary melanoma tumour by using 123I-IMP in ~91% [22].
Kato and co-workers applied 123I-IMP for ocular melanoma diag-
nostics by using SPECT imaging. This method gave better results
than 18F-FDG PET, which was characterized by a high percentage
of false negative results [35].
123I-IMP scintigraphy is difficult when melanoma is looked for in
brain, lungs, or liver due to the high physiological uptake of the
radiopharmaceutical in these organs [36].
Otsuka et al. demonstrated that detection of metastases to
the skeleton with IMP scintigraphy gave better results when com-
pared with conventional skeletal scintigraphy (with 99mTc-HMDP as
the radiopharmaceutical) [37].
Attempts to find a radiopharmaceutical
with specific affinity to melanoma cells
Alpha-methyltyrosine labelled with 123I
Tyrosine as a precursor in melanin synthesis may form an in-
teresting tracer for diagnostics of melanoma. In the 1980s, expe-
riments on cellular lines in vitro were promising [38, 39]. However,
the investigations of Boni et al. later gave discouraging results. There
was accumulation of alpha-methyltyrosine (AMT) in melanoma cells
of the M19 line (in culture), but studies in several patients (SPECT)
demonstrated a sensitivity of 37% when verified by the presence of
melatonic cells by 18F-FDG PET. In planar images, the melanoma
foci were not detected. Due to its low sensitivity, the tests with
123I-AMT were discontinued [40].
Radioimmunoscintigraphy
Radioimmunoscintigraphy utilizes monoclonal antibodies
(mAb) or their fragments (Fab), labelled with radioactive nuclide,
having a specific affinity to antigens present on neoplastic cells
[10, 41–43]. In the 1900s there were numerous tests utilizing anti-
bodies labelled with 99mTc (9.2.27, 255-28 S, NR-ML-05) and with
111In (96.5, ZME-018).
The results obtained in many laboratories indicated a high spe-
cificity (93–100%) but were disappointing where sensitivity was con-
cerned (49–74%). Blend and co-workers, while experimenting with
Fab fragments of a monoclonal antibody NR-ML-05 labelled with
99mTc, were able to reach a sensitivity of 86%. These authors esti-
mated the stadium of melanoma, and obtained correct results in
24 out of 26 cases; 4 neoplastic changes were found, the pres-
ence of which was not anticipated, and 2 cases were misdiag-
nosed as false negative [41].
Another laboratory of S.B. Sergiev used a 99mTc labelled frag-
ment Fab2 of the antibody 255-28 S for detection of ocular mela-
nomas. The sensitivity and specificity of the method reached 79
and 100%, respectively [43].
Wider use of radioimmunoscintigraphy in the diagnostics of
melanomas is hampered by several problems. Preparation of mon-
oclonal antibodies is very expensive and the same applies to de-
rived radiopharmaceuticals. Secondly, for ethical reasons, mouse
cells are used for in vitro preparation of antibodies with the result
that antibodies are nonhuman, which may lead to an undesired
reaction of patient's immunological system. There is a possible
solution for the last problem by using chimeric and “humanized”
antibodies. Finally yet importantly, monoclonal antibodies are large
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molecules which migrate slowly in the tissues, leading to high back-
ground after introduction of such a radiopharmaceutical into the
system.
Melanotropin analogues (alpha-MSH)
Melanoma cells have a high affinity to melanotropic hormone
(alpha-melanocyte stimulating hormone). The hormone stimulat-
ing melanocytes acts on the cell via a melanocortin receptor of
type 1 (MC1R), which, in the melanoma tissue, is over-expressed.
Numerous investigators directed their attention to the possible use
of MSH, connected to metal chelators, in the diagnostics of mela-
nomas. An MSH conjugate labelled with 111In and linked with metal
chelator DTPA (diethylenetriaminepentaacetic acid) demonstrat-
ed promising results for melanoma imaging. However, there was
a nonspecific uptake by some organs, e.g. the liver, which often
acts as a recipient for melanoma metastases [44, 45].
The 99mTc labelled (Arg11)-CCMSH and 111In labelled conjugate
of MSH derivative with metal chelator DOTA (111In-DOTA-
-Re(Arg11)-CCMSH) possessed a high affinity to experimental
melanoma tumours. The tumour/non-tumour ratios obtained were
very high for the majority of organs — with the exclusion of the
kidneys, which accumulated the tracer to high concentrations [46].
Another compound investigated by Froidevaux and co-work-
ers, an 111In labelled derivative of alpha-MSH containing eight amino
acids in the molecule and coupled to DOTA (111In-DOTA-MSHoct),
also displayed a high accumulation in the kidneys [44]. Other mod-
ifications of the structure with utilization for coupling to DOTA,
a C-end peptide, led to a new compound, DOTA-NAPamide, with
still higher affinity to MC1R receptor and reduced retention in the
kidneys. Utilizing a 68Ga positron emitting isotope for labelling, DOTA-
-NAPamide gives the chance to image the melanoma by PET [45].
A team led by L. Wei utilized a 68Ga labelled cyclic derivative,
DOTA-Re(Arg11)CCMSH, in PET imaging of experimental tumours
in animals [47]. The possibility to complex the DOTA-MSH deri-
vation with numerous radioactive cations, both 2- and 3-valid, as
well as strong specific binding of the complex with neoplastic cells,
also creates the chance to utilize these compounds in melanoma
therapy [44, 45].
Iodinated aminoalkyl benzamide derivatives
In the last few years there have been intensified investigations
aimed at finding a specific radiopharmaceutical for the diagnos-
tics of melanomas. Several compounds from the group of N-alky-
lated benzamide derivatives labelled with radioactive iodine nu-
clides (123I, 131I) were found that could be classified as potentially
useful [48–52]. A general formula of compounds from this group is
presented in Figure 1.
Preliminary investigations of several compounds yielded hope
that some of them might be useful for the evaluation of regional
lymph nodes, and for the detection of metastases in patients with
removed primary focus of the neoplasm.
IBZA
The most thorough investigations were concentrated on
N-(2-diethylaminoethyl)-4-iodobenzamide (IBZA). Michelot and co-
workers studied, under clinical conditions, 123I-IBZA as a potential
marker of melanoma foci and obtained sensitivity and specificity of
81 and 100%, respectively [51].
W. Brandau and his team imaged melanotic foci using the same
compound and confirmed presence of melanotic foci in all sus-
pected localizations [48]. In both studies, however, there was in-
tensive cumulation of the compound in the liver, which made de-
tection of metastases in the abdominal cavity very difficult.  The
long imaging time after injection of IBZA (18–24 h) was also un-
favourable, resulting from slow elimination of the radiopharmaceu-
tical from the body [52]. On the other hand, satisfying results were
obtained in diagnostics of ocular melanomas by SPECT 4 hours
after administration. Everaert and his co-workers detected ocular
melanomas in 9 out of 10 patients with clinically and radiologically
confirmed neoplasm. One false negative case was seen in a pa-
tient with a small, hypochromatic focus. At the same time, the au-
thors diagnosed as truly negative 4 cases in patients with ocular
pathology of other origin. Therefore, the specificity reached 100%
[49]. Similar results with another derivative of IBZA (iodine atom at
the 2-position of the benzene ring) were obtained by I. Sillaire Hout-
mann (sensitivity 78%, specificity 95) [53].
Figure 1. General structure of aminoalkyl benzamide derivatives.
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IBZM
IBZM, i.e. 2-hydroxy-3-iodo-6-metoxy-N-[(1-ethyl-2-pyrodi-
nyl)methyl] benzamide is a commercially available radiopharma-
ceutical from the group of benzamides used in neuropsychiatry
(Parkinson's disease, schizophrenia), which is utilized due to its
affinity to dopamine 2 and probably dopamine 3 receptors.
IBZM, labelled with radioiodine, was studied to ascertain if it
could be useful in the diagnostics of melanomas. However, the
maximum tumour/non-tumour ratio did not exceed 2.6 and was
similar to that seen by Brandau for 123I-IBZA . Intensive cumulation
of the compound in liver was similarly inconvenient [50].
IMBA
N-(2-diethylaminoethyl)-3-iodo-4-metoxybenzamide — IMBA
was synthesized while seeking a modified structure of IBZA that
would improve the pharmacokinetic properties of the potential ra-
diopharmaceutical by being faster excreted from the organism
(> 90% via urinary tract). IMBA also has less affinity to erythrocytes
and proteins of the serum and negligible binding by structures of
the brain.
Nicholl and co-workers demonstrated in preliminary studies
on a few patients that 123I-IMBA is characterized by high tumour/
/non-tumour ratios in as little as 4 hours after injection [54]. Studies
by Edreira and co-workers confirmed specific and high accumula-
tion of IMBA in melanotic tissue and a high tumour/non-tumour
ratio due to fast clearance of the compound from the body (in an-
imals) via the urinary tract (whole body retention 19.7 ± 7.1% at
6 h after administration and 4 ± 2.4%  at 24 hours after administra-
tion) [55]. High tumour/non-tumour ratios (153 ± 39 for blood,
176 ± 26 for intestines, 270 ± 107 for kidneys, and 448 ± 82 for
muscles) were obtained in animal models studied in the Depart-
ment of Nuclear Medicine of the Medical University of Lodz. This
give rise to a degree of optimism when applying IMBA as a new
and specific radiopharmaceutical for the diagnostics of melano-
mas in humans [56].
Conclusions
Malignant melanomas belong to the group of most aggressive
neoplasms. Appropriate staging of melanomas should improve
the treatment process. Due to its high capacity for metastatic
spread, the tumour requires accurate assessment of the spread
before and after the therapy. Nuclear medicine techniques are be-
ing improved and offer potential progress in diagnostics and per-
haps treatment. Lymphoscintigraphy of the sentinel node and
positron emission tomography (18F-FDG) already have an appro-
priate position in clinical practice. Further improvement should be
expected from combining functional with anatomic imaging in im-
age fusing (PET/CT, SPECT/CT). Numerous compounds labelled
with radionuclides have been tested for the diagnostics of melano-
mas. Some of these products did not find a permanent place in
clinical practice, others (melanotropin analogues, radioimmunos-
cintigraphic tracers, and particularly the aminoalkyl benzamide
derivatives seem to offer potential use in classical scintigraphic tech-
niques (planar, SPECT). Those that seem to be specific for mela-
notic cells may offer an alternative by more common application of
the PET technique. However, in spite of its usefulness and better
resolution, PET technology is still not a commonly available tech-
nique, particularly in less affluent countries. However, new radiop-
harmaceuticals specific for melanomas may offer better than usual
capacity for further PET diagnostics. In addition, new compounds
may enable the  detection of melanotic foci in numerous organs in
which 18F-FDG is not possible due to the physiologically high ac-
cumulation of fluorodeoxyglucose, an important case being the
detection of melanoma metastases in the brain.
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